QualityStocks News – Biovest International, Inc. (BVTI.OB) Reports Clinically and Statistically Significant Data from Phase 3 Trial of BiovaxID®

We would like to highlight Biovest International, Inc. (OTCBB: BVTI). The company is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics.

In the company’s recent news,

Biovest International, Inc. (BVTI.OB), a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system, and a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced clinically and statistically significant unblinded data from the company’s randomized controlled pivotal Phase 3 fast-tracked clinical trial of BiovaxID®, a treatment for non-Hodgkin’s lymphoma.

BiovaxID® is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient’s own immune system to recognize and destroy cancerous B-cells that may remain in the body after chemotherapy treatment. BiovaxID® is designed to kill only cancerous B-cells for patients diagnosed with non-Hodgkin’s lymphoma, unlike other traditional medical treatments, such as radiation and chemotherapy, which destroy healthy cells and cancerous cells throughout the body. BiovaxID® could potentially be useful in the treatment of other types of B-cell cancers, such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.

Originally developed and advanced into human clinical trials by the National Cancer Institute (NCI), the Phase 3 trial for BiovaxID® supported highly encouraging clinical evidence on vaccinated patients regarding efficacy and safety. Biovest International intends to move forward with plans to seek accelerated and/or conditional regulatory approvals in the United States and in Europe.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Dateline: Scottsdale, Arizona

URL: http://www.qualitystocks.net/

Email: editor@qualitystocks.net

C:\Users\Jonathan\Desktop\QualityStocks\Logos\QualityStocks Logo.jpg

quality, stocks, qualitystocks